UBS initiated coverage on Butterfly Network with a new price target
$BFLY
Medical Electronics
Health Care
UBS initiated coverage of Butterfly Network with a rating of Neutral and set a new price target of $7.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/10/2024 | $3.00 | Buy | Lake Street |
| 3/29/2023 | $2.25 | Neutral | UBS |
| 11/29/2022 | $4.50 | Outperform | Oppenheimer |
| 10/4/2022 | $9.50 | Buy | B. Riley Securities |
| 12/17/2021 | $7.00 | Neutral | UBS |
Delivered Quarterly Revenue of $20.6mm, 33% YoY Growth Raises Full Year Revenue and Adjusted EBITDA Guidance Delivered quarterly Revenue of $20.6 million in Q3, representing 33% YoY growth Reduced Q3 Net Loss by 38% and Net Cash Used in Operations by 50% Launched iQ3 in Europe and opened new markets in Indonesia, the Netherlands, and Belgium Announced the formation of Octiv™, a wholly owned subsidiary focused on bringing Butterfly's chip to new sectors Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced financial results for th
Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report third quarter 2024 financial results on November 1, 2024 at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Heather Getz, Executive Vice President and Chief Financial and Operations Officer, will host a conference call and webcast before the market opens on November 1 to discuss third quarter 2024 financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor
Reports Record Quarterly Revenue Raises Full Year Adjusted EBITDA Guidance Delivered record quarterly Revenue of $21.5 million in Q2, representing 16% YoY growth Reduced Q2 Net Loss by 45% and Net Cash Used in Operations by 62% Successfully launched medical school Campus Essentials program Launched iQ3 in Canada and expanded into new markets in Southeast Asia Filed for revocation of the RoHS handheld piezoelectric crystal ultrasound exemptions Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced financial results for t
With iQ+ Bladder, Butterfly expands outside its core point-of-care ultrasound market to better serve the bladder scanning market with its proprietary Ultrasound-on-Chip™ technology.The bundled bladder solution includes an iQ+ Bladder probe, streamlined software, compact rolling cart, tablet and power splitter, paired with premium assembly.Butterfly Network, Inc. ("Butterfly", "the Company") (NYSE:BFLY), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today introduced its first specialty product, iQ+ Bladder™, now available for purchase in the United States. The bundled solution includes an iQ+ Bladder
Gainers Allarity Therapeutics (NASDAQ:ALLR) stock moved upwards by 106.6% to $2.83 during Thursday's pre-market session. The market value of their outstanding shares is at $5.5 million. Emergent BioSolutions (NYSE:EBS) shares moved upwards by 52.84% to $2.95. The market value of their outstanding shares is at $154.5 million. As per the press release, Q1 earnings came out yesterday. Aptevo Therapeutics (NASDAQ:APVO) stock rose 35.41% to $1.3. The company's market cap stands at $4.6 million. Context Therapeutics (NASDAQ:CNTX) stock rose 34.55% to $1.83. The company's market cap stands at $29.2 million. Skye Bioscience (NASDAQ:SKYE) stock increased by 25.09% to $16.0. The company's market
Lake Street initiated coverage of Butterfly Network with a rating of Buy and set a new price target of $3.00
UBS initiated coverage of Butterfly Network with a rating of Neutral and set a new price target of $2.25
Oppenheimer initiated coverage of Butterfly Network with a rating of Outperform and set a new price target of $4.50
4 - Butterfly Network, Inc. (0001804176) (Issuer)
4 - Butterfly Network, Inc. (0001804176) (Issuer)
4 - Butterfly Network, Inc. (0001804176) (Issuer)
Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly") a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that its management will present and host one-on-one meetings at the virtual BTIG Digital Health Forum on November 25, 2024. Presentations at the event will include: 9:00 am ET Fireside Chat: Joseph DeVivo, President, Chief Executive Officer and Chairman, and Heather Getz, Executive Vice President, Chief Financial and Operations Officer, will discuss Butterfly's differentiated technology, strategic approach, and future opportunities. 3:00 pm ET Panel Discussion: John Martin, MD, Chief Medical Officer, will discuss t
Butterfly Network, Inc. ("Butterfly") (NYSE:BFLY), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today announced that Butterfly iQ3™, its third-generation handheld ultrasound device, was the recipient of the Best Medical Technology Award at the 2024 Prix Galien USA Awards by the Galien Foundation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241108425693/en/Butterfly Network's Chief Executive Officer, Joseph DeVivo; Co-Founder & VP of Core Technology, Nevada Sanchez; and Chief Strategy Officer, Darius Shahida, accept the Prix Galien US
Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly") a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced its participation at the Canaccord Genuity (CG) MedTech, Diagnostics and Digital Health & Services Forum in New York City on November 21, 2024. Joseph DeVivo, President, Chief Executive Officer & Chairman, and Heather Getz, Executive Vice President & Chief Financial and Operations Officer will host one-on-one meetings throughout the day, and Mr. DeVivo will deliver a business overview presentation at 11:00 am ET. A webcast of the presentation will be posted to the Events & Presentations section of the Butterfly investor w
10-Q - Butterfly Network, Inc. (0001804176) (Filer)
8-K - Butterfly Network, Inc. (0001804176) (Filer)
144 - Butterfly Network, Inc. (0001804176) (Subject)
4 - Butterfly Network, Inc. (0001804176) (Issuer)
4 - Butterfly Network, Inc. (0001804176) (Issuer)
4 - Butterfly Network, Inc. (0001804176) (Issuer)
SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)
SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)
SC 13G/A - Butterfly Network, Inc. (0001804176) (Subject)
Seasoned Healthcare Leader to Drive Growth Strategy and Amplify Continued Commercial Momentum Butterfly Network, Inc. (NYSE:BFLY), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced the appointment of Steve Cashman as Chief Business Officer (CBO), effective today. Cashman joins Butterfly at an exciting juncture, following the Company's successful launch of its third-generation Butterfly iQ3 and historic revenue performance in the first half of 2024. Cashman will join Butterfly's Executive Management Team, overseeing the Company's global sales, marketing, product and corporate strategy. This press release f
SAN FRANCISCO, Aug. 20, 2024 /PRNewswire/ -- Avive Solutions, Inc., a manufacturer of innovative Automated External Defibrillators (AEDs) and software solutions to improve access to AEDs and response to cardiac arrest emergencies, is excited to announce the appointment of Katerina Miras as their Vice President of Marketing. A visionary marketing leader with extensive experience in medtech, Miras brings a wealth of expertise in creating memorable healthcare brands that accelerate commercial growth. "I am honored to join Avive's leadership team at such a transformative time for
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin